VALANX Biotech, a pioneering company in the realm of biotechnology, recently announced a successful funding round, securing €3 million. This financial boost will facilitate the advancement of its lead antibody-drug conjugate (ADC) program, specifically targeting metastatic triple-negative breast cancer (mTNBC). The funding round attracted notable new investors, including Foundation Fournier-Majoie and FUJIFILM Corporation, who join a roster of existing venture capital partners such as xista science ventures, tecnet equity, SOSV, alongside angel investors Urs Spitz and SkyGene.
Advancing Pre-Clinical Development
The newly acquired capital will primarily support the pre-clinical development of VALANX’s VLX-ADC-001, an innovative ADC targeting LIV-1. The timeline for candidate selection is set for June 2026, marking a significant milestone in the therapeutic journey of this promising treatment. In addition, the funding will contribute to the company’s efforts in achieving Good Manufacturing Practice (GMP) readiness and bolster its initiatives for forming strategic partnerships related to the GoldenSite™ conjugation platform.
Strategic Board Appointment
As part of this financing initiative, Ana Maricevic has been appointed to VALANX’s Board of Directors. Representing the Foundation Fournier-Majoie, Maricevic’s expertise and insights are expected to enhance the company’s strategic direction and development efforts in oncology.
The Promise of ADCs
Antibody-drug conjugates represent a revolutionary class of therapies that merge the targeting capabilities of antibodies with potent cytotoxic agents. VALANX’s GoldenSite platform is designed to facilitate rapid, reproducible, and site-selectable conjugation. This innovative approach aims to refine the therapeutic window of ADCs, addressing a significant challenge in their development by balancing efficacy with reduced toxicity.
LIV-1 as a Target
LIV-1 has emerged as a promising target in the treatment of mTNBC, a particularly aggressive form of breast cancer. The flexibility offered by the GoldenSite platform allows for precise tuning of conjugation positions, optimizing the therapeutic characteristics of drug candidates. This capability is crucial for advancing VLX-ADC-001 toward a robust preclinical data package by the set deadline while simultaneously progressing towards GMP readiness and establishing partnerships with other innovators in the ADC space.
Industry Insights
Michael Lukesch, the Founder and CEO of VALANX Biotech, expressed enthusiasm about the potential of the LIV-1-targeting ADC and the strategic advancements made possible through the recent funding. He articulated the company’s commitment to overcoming challenges in ADC development, emphasizing the importance of optimizing therapeutic windows to enhance treatment efficacy.
Ana Maricevic of the Foundation Fournier-Majoie echoed this sentiment, highlighting the foundation’s mission to support innovative oncology projects with clear developmental pathways. She noted that VALANX’s focus on site-selectable conjugation directly addresses critical issues within the ADC field, particularly in managing toxicity to enhance overall efficacy.
Commitment from FUJIFILM
Toshihisa Iida, representing FUJIFILM Corporation, underscored the company’s dedication to advancing life sciences through strategic investments. He articulated FUJIFILM’s intent to align with cutting-edge technologies that are shaping the next generation of biologics. Iida’s comments reflect a broader commitment to fostering a robust ecosystem that supports the development and delivery of advanced therapeutic solutions.
Conclusion
In summary, VALANX Biotech’s recent €3 million funding acquisition marks a pivotal step forward in the development of its LIV-1 ADC for metastatic triple-negative breast cancer. With strategic partnerships and a focus on innovative technology, VALANX is poised to make significant strides in the oncology space. The collaboration between new and existing investors, alongside the commitment to enhancing ADC technology, sets the stage for transformative advancements in cancer treatment.
- Key Takeaways:
- VALANX Biotech secured €3 million for its LIV-1 ADC program.
- The funding will support pre-clinical development and GMP readiness.
- The GoldenSite platform enhances site-selectable conjugation for better therapeutic outcomes.
- LIV-1 is a critical target for treating aggressive forms of breast cancer.
- Strategic partnerships are integral to advancing the company’s goals in oncology.
Read more → www.news-medical.net